Table 2 Clinical effects of eribulin chemotherapy in breast cancer subtype
All breast cancer (n = 52) | Intrinsic subtype | ||
|---|---|---|---|
non-Triple-negative (n = 30, 57.7%) | Triple-negative (n = 22, 42.3%) | ||
ORR; Objective Response Rate | 18 (34.6%) | 12 (40.0%) | 6 (27.3%) |
CBR; Clinical Benefit Response | 23 (44.2%) | 15 (50.0%) | 8 (36.4%) |
DCR; Disease Control Rate | 27 (51.9%) | 18 (60.0%) | 9 (40.9%) |
CR; Complete Response | 1 (1.9%) | 1 (3.3%) | 0 (0.0%) |
PR; Partial Response | 17 (32.7%) | 11 (36.7%) | 6 (27.3%) |
SD; Stable Disease >24wks | 5 (9.6%) | 3 (10.0%) | 2 (9.1%) |
SD; Stable Disease | 4 (7.7%) | 3 (10.0%) | 1 (4.5%) |
PD; Progressive Disease | 20 (38.5%) | 7 (23.3%) | 13 (59.1%) |
NE; Not Evaluable | 5 (9.6%) | 5 (16.7%) | 0 (0.0%) |